Floyd F. Petersen Sells 500 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $28.38, for a total value of $14,190.00. Following the completion of the sale, the director now directly owns 73,909 shares in the company, valued at approximately $2,097,537.42. The trade was a 0.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Amphastar Pharmaceuticals Stock Down 1.7 %

Shares of AMPH traded down $0.49 during mid-day trading on Wednesday, hitting $27.80. 717,774 shares of the company’s stock were exchanged, compared to its average volume of 442,259. The stock’s 50-day moving average is $30.78 and its 200-day moving average is $39.63. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $25.89 and a fifty-two week high of $53.96. The company has a market cap of $1.32 billion, a price-to-earnings ratio of 9.27, a P/E/G ratio of 2.19 and a beta of 0.79.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Friday, March 21st.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC grew its stake in shares of Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after acquiring an additional 493 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock valued at $36,000 after purchasing an additional 871 shares during the period. GF Fund Management CO. LTD. acquired a new position in Amphastar Pharmaceuticals during the 4th quarter worth $38,000. Tower Research Capital LLC TRC increased its holdings in Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock worth $43,000 after purchasing an additional 348 shares during the period. Finally, Huntington National Bank increased its holdings in Amphastar Pharmaceuticals by 36.9% during the 4th quarter. Huntington National Bank now owns 1,340 shares of the company’s stock worth $50,000 after purchasing an additional 361 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.